Michele W. L. Teng

Michele W. L. Teng

Auto-generated profile, based on publicly available information

Michele W. L. Teng

QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2018 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JOJake S. O’dOnnell
Jake S. O’dOnnell
MTMichele W. L. Teng
Michele W. L. Teng
MSMark J. Smyth
Mark J. Smyth

31 May 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
MTMichele W.L. Teng
Michele W.L. Teng
SNShin Foong Ngiow
Shin Foong Ngiow
ARAntoni Ribas
Antoni Ribas
MSMark J. Smyth
Mark J. Smyth
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. There are numerous immune cell types found in cancers and many components of an immune reaction to cancer. Thus, the tumor has many strategies to evade an immune response. It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of tumor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression. We review this stratification and the latest in a series of results that shed light on new approaches for rationally designing ideal combination cancer therapies based on tumor immunology. Cancer Res; 75(11); 2139–45. ©2015 AACR.

16 October 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MKMaya Kansara
Maya Kansara
MTMichele W. Teng
Michele W. Teng
MSMark J. Smyth
Mark J. Smyth
DTDavid M. Thomas
David M. Thomas

1 December 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
SBStephen J. Blake
Stephen J. Blake
MYMichelle C.R. Yong
Michelle C.R. Yong
HHHeidi Harjunpää
Heidi Harjunpää
SNShin Foong Ngiow
Shin Foong Ngiow
MTMichele W.L. Teng
Michele W.L. Teng
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293

29 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
MTMichele W L Teng
Michele W L Teng
EBEdward P Bowman
Edward P Bowman
JMJoshua J McElwee
Joshua J McElwee
MSMark J Smyth
Mark J Smyth
JCJean-Laurent Casanova
Jean-Laurent Casanova
DCDaniel J Cua
Daniel J Cua

15 May 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
SNShin Foong Ngiow
Shin Foong Ngiow
BSBianca von Scheidt
Bianca von Scheidt
HAHisaya Akiba
Hisaya Akiba
HYHideo Yagita
Hideo Yagita
MTMichele W. L. Teng
Michele W. L. Teng
MSMark J. Smyth
Mark J. Smyth
Strategies to activate and rescue exhausted tumor-specific T cells, including the use of monoclonal antibodies (mAb) that block the negative costimulatory receptors CTLA-4 and PD-1 are proving very effective, but TIM3 has been relatively neglected as a target. Here we report an extensive characterization of the therapeutic activity and mechanism of action of an anti-mouse TIM3 mAb against experimental and carcinogen-induced tumors. For the first time we specifically define the mechanism of antitumor action of anti-TIM3 requiring IFN-γ producing CD8+ T cells and CD4+ T cells, and a higher ratio of tumor infiltrating CD8+:CD4+ T cells correlating with therapeutic success. Interestingly, in some models, anti-TIM3 appeared to be effective sometime before the appearance and accumulation of significant TIM3+PD-1+ T cell populations in tumor bearing mice. Anti-TIM3 displayed modest prophylactic and therapeutic activity against a small fraction of carcinogen-induced sarcomas, but comparative and combination studies of anti-TIM3 with anti-CTLA-4 and anti–PD-1 against experimental and carcinogen-induced tumors suggested that these agents might be well-tolerated and very effective in combination. Cancer Res; 71(10); 3540–51. ©2011 AACR.